Goodwin advised Flagship Pioneering on the matter. Hogan Lovells acted for Omega Therapeutics, Inc. Novo Nordisk, Omega Therapeutics, Inc. (Nasdaq: OMGA) and Cellarity Inc. announced that Novo Nordisk...
You must be a Standard 1 Year member to access this content.
Goodwin advised the initial purchasers on Amphastar Pharmaceuticals, Inc.’s offering. Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced the Rule 144A offering of 2.00% Convertible Senior Notes due...
You must be a Standard 1 Year member to access this content.
Goodwin Procter advised Advanced Biologics in its merger with Isto Biologics. Isto Biologics, a portfolio company of TSCP and a global leader in regenerative and autologous...
You must be a Standard 1 Year member to access this content.
Goodwin advised Scholar Rock Holding Corporation on the offering. Scholar Rock Holding Corporation (Nasdaq: SRRK), a Phase 3 clinical-stage biopharmaceutical company focused on the treatment of serious...
You must be a Standard 1 Year member to access this content.
Latham & Watkins advises Revolution Medicines on the deal, and Goodwin Procter advises EQRx. Revolution Medicines, Inc. (Nasdaq: RVMD) and EQRx, Inc. (Nasdaq: EQRX) announced a definitive agreement...
You must be a Standard 1 Year member to access this content.
Goodwin Procter advised Avadel Pharmaceutics plc on the deal. Avadel Pharmaceuticals announced an underwritten public offering of 10,000,001 of its ordinary shares, nominal value $0.01 per...
You must be a Standard 1 Year member to access this content.
Goodwin Procter advised BridgeBio Pharma on the offering, and Latham & Watkins advised the underwriters involved. BridgeBio Pharma, Inc. announced the pricing on March 7, 2023 of...
You must be a Standard 1 Year member to access this content.
Goodwin Procter advised Scholar Rock Holding Corporation on the deal. Scholar Rock Holding Corporation announced the completion of its registered direct offering of 16,326,530 shares of common...
You must be a Standard 1 Year member to access this content.
Goodwin Procter advised BridgeBio Pharma, Inc. on the deal. BridgeBio Pharma, Inc. (Nasdaq: BBIO) announced its exclusive license agreement wit Bristol Myers Squibb to develop and...
You must be a Standard 1 Year member to access this content.
Goodwin Procter advised Bio Products Laboratory and Tiancheng International Investment Limited on the deal. The shareholders of Kedrion was advised by Carnelutti and Pedersoli Studio Legale,...
You must be a Standard 1 Year member to access this content.
Goodwin Procter advised Human Care Systems on the deal. Human Care Systems, Inc. announced its sale to CareMetx, LLC. Human Care Systems is a company focused on...
You must be a Standard 1 Year member to access this content.
Goodwin advised Aldrich Capital Partners on the deal. Aldrich Capital Partners announced its acquisition of Compliancy Group, LLC. Aldrich is a growth equity firm supporting disruptive innovation...
You must be a Standard 1 Year member to access this content.
